Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: a preliminary study

Tong Zhao, Qiang Lu, Yong Tao, Xiao-Ying Liang, Kai Wang, Yan-Rong Jiang

Department of Ophthalmology, People’s Hospital, Peking University, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing, China

Purpose: To examine the intraocular distribution of bevacizumab at four weeks after intravitreal bevacizumab (IVB) injection and to investigate the effects of IVB on apelin and vascular endothelial growth factor (VEGF) in the central retinal vein occlusion (CRVO) of monkey eyes.

Methods: Direct laser coagulation was performed on all branch retinal veins in the right eyes of six Rhesus monkeys to establish a CRVO model. The eyes of the first three monkeys were enucleated one week, two weeks, and 24 weeks after the establishment of the CRVO model; this was the CRVO group. Subsequently, IVB was injected into the eyes of the last three monkeys one week, two weeks, and 24 weeks after laser coagulation; this was the IVB group. The left eye of the first monkey was used as normal control. Immunohistochemistry and reverse-transcription PCR was used to examine the expression of apelin and VEGF. The penetration of bevacizumab into the retina and iris was investigated by fluorescence immunostaining.

Results: Immunoreactivity for bevacizumab could be detected in the vessel walls of the iris and choroid on day 28 after injecting IVB: apelin and VEGF staining had been more prominent than normal in the CRVO eye, but these decreased following IVB injection. Expression of apelin mRNA (p<0.01) was lower in the IVB group than the CRVO group and did not vary significantly between groups.

Conclusions: Bevacizumab could be detected in the iris and choroid after four weeks of intravitreal injection. Apelin may be partially suppressed by bevacizumab, and it may play a role in retinal neovascularization during the development of CRVO.

Central retinal vein occlusion (CRVO) is one of the most common retinal vascular diseases involving blindness [1]. Macular edema, caused by a decline in the blood–retina barrier, contributes to central vision loss. The decreased tissue perfusion leads to possible neovascular complications, such as rubeosis iridis and neovascular glaucoma, which can severely influence quality of life [2,3]. At present, photocoagulation has been widely used in CRVO to prevent neovascular complications. However, it cannot improve vision prognosis. Some evidence suggests that repeated intravitreal injections of triamcinolone may improve vision, but the complication of intraocular pressure and cataract makes it a less than ideal treatment [4].

The pathogenesis of CRVO is not very well understood and remains controversial. However, it is widely accepted that vascular endothelial growth factor (VEGF) plays an important role in CRVO development [5]. Anti-VEGF therapy, including intravitreal bevacizumab (IVB), has proven to be effective in improving visual acuity and inhibiting neovascularization [6,7]. However, research has revealed that anti-VEGF alone cannot completely prevent the occurrence of new vessels, which indicates that other factors may also participate in the process of neovascularization apart from VEGF [8]. Apelin is reported to act as an angiogenic factor that could stimulate the proliferation and migration of retinal endothelial cells and vascular tube formation [9,10]. That function cannot be replaced by VEGF [11]. Besides, recent studies suggest that apelin may be involved in retinal neovascularization during the development of proliferative diabetic retinopathy [12]. In an eye with CRVO, hypoperfusion causes stasis of the retinal bloodstream and retinal tissue hypoxia, which may induce upregulation of apelin, thereby simulating neovascularization.

To evaluate the potential effect of apelin in the pathogenesis of CRVO, we conducted the present study to examine whether bevacizumab could be detected four weeks after IVB and to investigate the expression of apelin in eyes with central retinal vein occlusion and the effect of bevacizumab.

METHODS

Establishment of CRVO model: We established the CRVO model by obstructing all major retinal branch veins (usually
two to three veins) of single eyes in six rhesus monkeys. All investigation involving animals conformed to the guidelines of the Association for Research in Vision and Ophthalmology’s Resolution Statement for the Use of Animals in Ophthalmic and Vision Research. The veins were obstructed completely and permanently by mean of a green argon laser (Novus Omni system; Coherent Lambda Physik, Dieburg, Germany) with energy of 400–500 mW. Among the six eyes, five eyes received a second laser photocoagulation. Grouping of animals: Animals were numbered No. 1 to No. 6 and divided into different groups, as shown in Table 1. The left eye of No. 1 was used as the normal control. The right eyes of No. 1, 2, and 3 were enucleated one week, two weeks, and 24 weeks after the establishment of the CRVO model. These were used as the CRVO group and named “1 w,” “2 w,” and “24 w,” respectively. The right eyes of No. 4, 5, and 6, which were enucleated four weeks after intravitreal injection of bevacizumab, were defined as the IVB group and named “1 w + IVB,” “2 w + IVB,” and “24 w + IVB,” respectively. In the IVB group, No. 4, 5, and 6 differed in the intervals between the establishment of the CRVO model and intravitreal injection of bevacizumab, which were one week, two weeks, and 24 weeks, respectively.

Intravitreal injection of bevacizumab: Bevacizumab (Avastin; Roche, San Francisco, CA) with dosage of 0.05 ml (1.25 mg) was injected into the vitreous cavity under sterile conditions. Before injection, an anterior chamber puncture was made to maintain normal intraocular pressure. The animals were anesthetized with intramuscular injection of 30 mg/kg bodyweight ketamine hydrochloride (Ketalar, Parke-Davis, Morris Plains, NJ). Routine ocular examinations were done immediately after injection, in case of retina or lens injury. Levofloxacin Eye Drops (Santen Pharmaceutical Co., Ltd., Ishikawa, Japan) were administered from this time point four times a day for 4 days to prevent infection. Animals were monitored for signs of inflammation until euthanasia with intramuscular injection of 10 mg/kg ketamine hydrochloride (Ketalar, Parke-Davis) followed by intravenous 100 mg/kg pentobarbital sodium (Sigma-Aldrich, St. Louis, MO).

Fluorescence immunostaining: Eyes were enucleated, fixed in formalin, embedded in paraffin wax, sectioned, and deparaffinized. Goat fluoresceinisothiocyanate-conjugated anti-human immunoglobulin G (IgG; Zhongshan Goldenbridge Biotechnology, Beijing, China) was used to detect bevacizumab at a dilution of 1:50. Following incubation, the slides were washed and stained with 4’,6’-diamino-2-phenylindole (DAPI, No. D9542; Sigma-Aldrich, St. Louis, MO) at a dilution of 1:1000. The slides were examined with a fluorescence microscope (DS-Ril-U2; Nikon, Tokyo, Japan), and images were acquired with a digital camera (DS-U2, Nikon).

Hematoxylin and eosin staining and immunohistochemistry: Routine hematoxylin and eosin (H&E) staining was performed. Immunohistochemistry was performed with rabbit anti-apelin polyclonal IgG (No. ab59469; Abcam, Cambridge, MA) at a dilution of 1:200 or mouse anti-VEGF polyclonal IgG (No. sc-7269; Santa Cruz Biotechnology, Santa Cruz, CA) at a dilution of 1:100. Biotin-conjugated goat antimouse IgG (Zhongshan Goldenbridge Biotechnology) were used as second antibodies, followed by DAB imaging. Photographs

| Number | Eye | Time (w) | Group | Group name | Description |
|--------|-----|---------|-------|------------|-------------|
| 1      | OS  | -       | Control | Normal     | -           |
| 1      | OD  | 1*      | CRVO   | 1 w        | Photocoagulation |
| 2      | OD  | 2       |        | 2 w        | Photocoagulation |
| 3      | OD  | 24*     | IVB    | 24 w       | Photocoagulation |
| 4      | OD  | 4**     | IVB    | 1 w + IVB  | IVB at 1 week after photocoagulation |
| 5      | OD  | 4**     | IVB    | 2 w + IVB  | IVB at 2 weeks after photocoagulation |
| 6      | OD  | 4**     | IVB    | 24 w + IVB | IVB at 24 weeks after photocoagulation |

* represents the time (weeks) between creation of retinal vein occlusion and the enucleation. ** represents the time (weeks) between intravitreal injection of bevacizumab and the enucleation.

| Name                                    | Primers (5′-3′)                             | Product length |
|-----------------------------------------|---------------------------------------------|----------------|
| human apelin                            | F: CACCTCGCACCTGCTGTA                       | 119 bp         |
|                                         | R: GAACGGGAATCATCCAAAC                      |                |
| human vascular endothelial growth factor| F: TCCCCCTTGGGATCCCAG                       | 91 bp          |
|                                         | R: GCCCGGGAGGAGGTGTTAG                      |                |
| Glyceraldehydes 3-phosphate dehydrogenase| F: GAGTCACCTGGCGTCTTCAC                    | 120 bp         |
|                                         | R: GTTCACACCTATGACGAACA                     |                |
Detection of mRNA by reverse-transcription PCR: The embedded retinal tissue was sectioned, deparaffinized, and digested in proteinase-K (P6556; Sigma-Aldrich, St. Louis, MO). Total RNA was extracted from the retinal tissues of all groups. Two micrograms of RNA were converted into cDNA in a total reaction volume of 25 µl, and the reverse transcription product (1 µl) was then amplified by reverse-transcription PCR. The specific primers of human VEGF, human apelin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were listed in Table 2. PCR products were electrophoretically separated on 2% agarose gel in a 1× tris-borate-EDTA (TBE) buffer. The optical density of each band was determined using BandScan software 4.5 (Glyko, Inc., Hayward, CA). For each band, five values were generated following the same procedure. The densitometric values for apelin and VEGF were normalized using GAPDH levels.
Statistical analyses: The statistical analysis was performed using a commercially available statistical software package (Statistical Package for Social Sciences for Windows, version 17.0; SPSS, Chicago, IL). Tests for independent samples were performed to compare differences in densitometric values for apelin or VEGF. Two-tailed probabilities of less than 0.05 were considered to indicate statistical significance.

RESULTS

Establishment of the central retinal vein occlusion model: The CRVO model was successfully established. On the first day after photocoagulation, fundus photograph showed laser photocoagulation spots and dilated retinal veins (Figure 1B), compared to normal fundus (Figure 1A).

A normal H&E section is shown in Figure 2A. Acute retinal edema was remarkable at 7 days after photocoagulation (Figure 2B). Disordered retinal structure was observed 24 weeks after the establishment of the CRVO model (Figure 2C).

Fluorescence immunostaining of bevacizumab: In the IVB group, bevacizumab was detected in the iris and choroid vessels (Figure 3) of all eyes at four weeks after intravitreal injection. There was no obvious difference among the three groups of “1 w+IVB,” “2 w+IVB” and “24 w+IVB.”

Immunohistochemistry of vascular endothelial growth factor: In normal monkey eyes, VEGF was detected in retinal vessel walls (Figure 4). In the iris tissue, there was no positive finding.

As to CRVO groups, VEGF was detected in retinal vessel walls (Figure 5A-C). By contrast, there was no obvious positive staining in the IVB groups. In group “24 w+IVB,” in addition to VEGF-positive staining, disordered retinal structure and increased vessels were found. In the iris, VEGF was also detected in CRVO groups, and the amount of vessels increased with the prolongation of the course of the disease (Figure 6A-C). In the IVB group, VEGF could not be detected (Figure 6D-E).
Immunohistochemistry of apelin: Similar to VEGF, apelin was detected in normal retinal vessel walls but not in the iris (Figure 4). Apelin-positive staining was seen in the retinal inner nuclear layer, outer nuclear layer, and ganglion cells (Figure 7A-C), apart from the vessel walls. The prolongation of the course of the disease seemed to have nothing to do with apelin staining. In the IVB groups, decreased apelin staining was observed, and the distribution was similar to that of the normal eyes, except for the “24w+IVB” group (Figure 7D-E). Apelin was stained in the iris blood vessels, and expression was down-regulated after IVB injection (Figure 8).

Expression of mRNA of vascular endothelial growth factor and apelin: The results of the PCR from the retinal tissue of each group are shown in Figure 9A. Expression of VEGF and apelin mRNA was observed in the normal monkey eye. In all stages for the CRVO groups, the expression of VEGF mRNA was upregulated, compared to the normal group (p<0.01). In the “24 w” group, the expression of VEGF mRNA was lower than in the “1 w” and “2 w” groups, but still higher than normal (p<0.01). After IVB, VEGF mRNA of all the three CRVO groups decreased significantly (all p<0.01); however, the VEGF mRNA level did not vary significantly between “1 w +IVB” group, “2w+IVB” group and “24w+IVB” group and normal control (p=0.71, 0.12, and 0.24, respectively; Figure 9B). The expression of apelin mRNA in the CRVO group was significantly higher than in the normal eyes (p<0.01). In the IVB group, the expression of apelin mRNA was lower than in the CRVO group (p<0.01), but was still higher than normal (p<0.01; Figure 9C).

DISCUSSION
Previous studies have indicated that bevacizumab can penetrate quickly into all layers of the retina and iris after intravitreal injection [13,14]. Some researchers revealed that bevacizumab could be detected two weeks after intravitreal injection [15,16]. In this study, it was found that bevacizumab was stained in choroid vessels and iris vessel walls four weeks after intravitreal injection. This result confirmed the accumulation location of bevacizumab, consistent with previous studies, and prolonged the recognized time of bevacizumab immunoactivity after intravitreal injection. We speculate that gelatinous vitreous functions as a kind of sustained release system for the diffusion of bevacizumab. On the other hand, disturbed circulation in local blood vessels and slow perfusion may also contribute to the accumulation of bevacizumab in some vessels [14]. Further research about the distribution of bevacizumab in different diseases will be helpful in determining the optimum interval between repeated intravitreal injections of bevacizumab.

The results of immunochemistry indicated that VEGF was down-regulated after intravitreal injection of bevacizumab, which agreed with previous reports that intravitreal bevacizumab lowered the concentration of VEGF in aqueous fluid and vitreous [17-19]. However, research findings have varied on the effects of bevacizumab on VEGF mRNA expression [20,21]. We found that the expression of VEGF mRNA decreased four weeks after intravitreal injection of bevacizumab. These results suggest bevacizumab improves the ischemic state and subsequently lowers the secretion-inducing pressure of VEGF. The upregulation of VEGF mRNA immediately after intravitreal injection is supposedly related to feedback regulation, due to the sharp drop in VEGF concentration from bonding with bevacizumab.

Apelin was first extracted in 1998 [9]. It has been reported to stimulate the proliferation and migration of retinal
endothelial cells, as well as to promote vascular tube formation [10]. Research implies that apelin might also participate in regulating new blood vessel growth in embryonic angiogenesis and tumor growth [11,22-24]. A study on the role of apelin in diabetic retinopathy showed there was a high vitreous concentration of apelin in eyes with proliferative diabetic retinopathy, as shown by immunofluorescence staining of apelin in the endothelial cells of the fibrovascular membranes of patients with proliferative diabetic retinopathy [12]. The above findings indicate that apelin might be an angiogenic factor that plays an important role in the pathogenesis of vascular disease, including retinal vein occlusion.

Figure 5. Immunochemistry of vascular endothelial growth factor in a retina. Sections of retina were examined by immunohistochemistry with anti-vascular endothelial growth factor (VEGF) antibody. Positive staining (brown) of VEGF was detected in retinal vessel walls in the central retinal vein occlusion groups (A: group “1 w,” B: group “2 w,” C: group “24 w”). There was no obvious positive staining after intravitreal bevacizumab (IVB) injection (D: group “1 w+IVB,” E: group “2 w+IVB,” F: group “24 w+IVB”).
Our results also showed that apelin was expressed in the vascular system, which was consistent with previous studies [12]. It was further found that in the CRVO eyes, apelin was also stained in the inner and outer nuclear layers. It has been speculated that the cells of the inner and outer nuclear layers, apart from vascular endothelial cells stimulated by hypoxia, secrete apelin in the manner of autocrine and paracrine [11].

Apelin sequentially affected the endothelial cells, promoting angiogenesis and proliferation. Apelin may play an important role in the development of CRVO. We observed that after intravitreal injection of bevacizumab, 1) apelin staining decreased, 2) the expression of apelin mRNA was down-regulated, and 3) the down-regulation did not return to normal levels, indicating that apelin expression may be suppressed by...
anti-VEGF therapy; but the extent of suppression is not parallel with that of VEGF. Apelin may be partially regulated with VEGF, to some extent. At the same time, apelin has an independent, upstream signaling pathway. It was also observed that apelin was still detected in the inner and outer nuclear layers in the “24 w” group, instead of in the “1 w” or “2 w” groups. We speculate that in the earlier stage, the effect of hypoxia on the cells of the inner and outer nuclear layers is reversible, and can be eliminated when anti-VEGF therapy improves hypoxia. In late-stage CRVO, cells of the inner and outer nuclear layers are irreversibly injured, and begin releasing apelin persistently.
There remain some potential limitations in our study. First, this is a preliminary study. Due to the small number of animals and lack of fresh tissue, some tests were not performed, such as western blotting, which would have provided more-accurate quantitative evidence. Second, rhesus monkeys were used as the experimental model. We cannot exclude the possibility that the humanized antibody bevacizumab interfered with the monkey’s immunology. More evidence needs to be produced to translate these conclusions from monkey to humans. Third, the investigation of the interaction between apelin and VEGF did not involve the molecular signaling level. Our deductions lack sufficient experimental support. In addition, previous studies revealed that apelin mainly promoted the growth of immature vessels.

Figure 8. Immunochemistry of apelin in an iris. Sections of iris were examined by immunohistochemistry with anti-apelin antibody. Positive staining (brown) of apelin was detected in iris vessel walls in the central retinal vein occlusion groups (A: group “1 w,” B: group “2 w,” C: group “24 w”), and there was no obvious positive staining in the intravitreal bevacizumab (IVB) groups (D: group “1 w+IVB,” E: group “2 w+IVB,” F: group “24 w+IVB”).
A study on the earlier acute stage of CRVO may be necessary and important.

In conclusion, bevacizumab could be detected after four weeks of intravitreal injection. Apelin staining was prominent, and the expression of apelin mRNA was significantly higher in the CRVO group. Intravitreal injection of bevacizumab down-regulated the expression of apelin mRNA, to some extent. These results suggest that apelin may play a role in the development of CRVO, and that apelin has a unique upstream signaling pathway, independent of the VEGF pathway.

ACKNOWLEDGMENTS

This study was supported by National Natural Science Foundation of China (No:30901639 and No:81041005), Beijing Novel Program (No:2009B04), Beijing Natural Science Foundation (No:7112142), the Science and Technology Project of Beijing (No:Z08000303220801),
Research Fund for the Doctoral Program of Higher Education of China (No:2010000110073) and EFSD/CDS/Lilly grant.

REFERENCES

1. Arevalo JF, Garcia RA, Wu L, Rodriguez FJ, Dalmau-Weiszhausz J, Quiroz-Mercado H, Morales-Canton V, Roca JA, Berrocal MH, Graue-Wiechers F, Robledo V. Pan-American Collaborative Retina Study Group. Radial optic neurotomy for central retinal vein occlusion: results of the Pan-American Collaborative Retina Study Group (PACORES). Retina 2008; 28:1044-52. [PMID: 18779709]

2. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney WE, Schwartz SG, Lee WH, Murray TG. Long-term safety and efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2010; 88:18-26. [PMID: 19794946]

3. Hou J, Tao Y, Jiang YR, Li XX, Gao L. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chin Med J (Engl) 2009; 122:2695-9. [PMID: 19951598]

4. Jiang Y, Liang X, Li X, Tao Y, Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2009; 87:736-40. [PMID: 18803622]

5. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251:471-6. [PMID: 9792798]

6. Kasi A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, Hinuma S, Baba A. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004; 325:395-400. [PMID: 15530405]

7. Kalin RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, Brandli AW. Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol 2007; 305:599-614. [PMID: 17412318]

8. Tao Y, Lu Q, Jiang YR, Qian J, Wang JY, Gao L, Jonas JB. Apelin in Plasma and Vitreous and in Fibrovascular Retinal Membranes from Patients with Proliferative Diabetic Retinopathy. Invest Ophthalmo Vis Sci 2010; 51:4237-42. [PMID: 20220056]

9. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemsenn F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U, Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmo Vis Sci 2007; 48:2814-23. [PMID: 17525217]

10. Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U. Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primare eye. Br J Ophthalmol 2008; 92:541-4. [PMID: 18211933]

11. Julien S, Heiduschka P, Hofmeister S, Schraermeyer U. Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primare eye: implication for the treatment of retinal vein occlusion. Br J Ophthalmol 2008; 92:1424-8. [PMID: 18815425]

12. Lassota N, Prause JU, Scherfig E, Kielgaard JF, la Cour M. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization. Acta Ophthalmol 2010; 88:300-8. [PMID: 19416113]

13. Park SP, Ahn JK. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Clin Experiment Ophthalmol 2009; 37:490-5. [PMID: 19624346]

14. Lim TH, Bae SH, Cho YJ, Lee JH, Kim HK, Sohn YH. Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol 2009; 23:188-92. [PMID: 19794946]

15. Miyake T, Sawada O, Kakinoki M, Sawada T, Kamamura H, Ogasawara K, Ohji M. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmo Vis Sci 2010; 51:1606-8. [PMID: 19875666]

16. Zhao Q, Zhang J, Guan Y, Zhang S, Zhu C, Xu GT, Wang L. Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 247:919-27. [PMID: 19301028]

17. Kim EC, Lee WS, Kim MS. The inhibitory effects of bevacizumab eye drops on NGF expression and corneal wound healing in rats. Invest Ophthalmo Vis Sci 2010; 51:4569-73. [PMID: 20393106]

18. Cox CM, D’Agostino SL, Miller MK, Heimark RL, Krieg PA. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 2006; 296:177-89. [PMID: 16750822]

19. Saint-Geniez M, Masri B, Malecaze F, Knibiehler B, Audigier Y. Expression of the murine msr/apj receptor and its ligand apelin in the anterior chamber of the primate eye. Invest Ophthalmo Vis Sci 2007; 48:9715-24. [PMID: 17744830]

20. Sorli SC, Le Gonidec S, Knibiehler B, Audigier Y. Apelin is a potent activator of tumour neoangiogenesis. Oncogene 2007; 26:7692-9. [PMID: 17563744]
